Biolinq

Biolinq's patch is placed on the upper forearm and utilises miniscule electrochemical sensors. A display indicates when glucose levels are at an optimum level, and works in real time for optimised and reliable insights. The device stands out against competing device by being "so small that you can barely feel it".

The company's oversubscribed 2024 funding round exemplifies how attractive the offering is to investors, as well as to consumers wanting to control their blood sugar level. Despite this promising market, however, Biolinq must still prove itself in the eyes of the FDA. Hence, funding will be used for a US clinical trial that will be pivotal for the device’s future.